Drug Truths: Dispelling the Myths about Pharma R&D

Drug Truths: Dispelling the Myths about Pharma R&D

Volumn , Issue , 2008, Pages 1-136

  LaMattina, John L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889823394     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470434673     Document Type: Book

References (159)

1. O'Connor, C. M., Dunne, M. W., Pfeffer, M. A., Muhlestein, J. B., Yao, L., Gupta, S., Benner, R. J., Fisher, M. R., and Cook, T. D. (2003). Azithromycin for the secondary prevention of coronary heart disease events. Journal of the American Medical Association 290, 1459-1466.
2. Grayson, J. T., Kronmal, R. A., Jackson, L. A., Parisi, A. F., Muhlestein, J. B., Cohen, J. D., Rogers, W. J., Crouse, J. R., Borrowdale, S. L. Schron, E., and Knirsch, C. (2005). Azithromycin for the secondary prevention of coronary events. New England Journal of Medicine 352, 1637-1645.
3. Cannon, C. P., Braunwald, E., McCabe, C. H. Grayson, J. T., Muhlestein, B., Giugliano, R. P., Cairns, R., and Skene, A. M. (2005). Antibotic treatment of Chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine 352, 1646-1654.
4. An excellent overview of the early history of this field is: Steinberg, D., and Gotto, A. M. (1999). Preventing coronary artery disease by lowering cholesterol levels; fifty years from bench to bedside. Journal of the American Medical Association 282, 2043-2050.
5. Moore, T. J. (1989). The cholesterol myth. The Atlantic Monthly 264, 37.
6. Castelli, W. P. (1984). Epidemiology of coronary heart disease: The Framingham study. American Journal of Medicine 76 (Suppl 2A), 4-12.
7. Lipid Research Clinics Program (1984). The Lipid Research Clinics Coronary Primary Prevention Trial Results. Journal of the American Medical Association 251, 351-374.
8. NIH Consensus Development Conference (1985). Lowering blood cholesterol to prevent heart disease: NIH Consensus Development statement. Nutritional Reviews 43, 283-291.
9. Tolbert, J. A. (2003). Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews, Drug Discovery 2, 517-526.
10. These patients are known to have heterozygous familial hypercholesterolemia. This is a relatively common genetic disorder occurring in about 0.2% of the population. These patients have reduced ability for their liver to remove LDL cholesterol from the blood. As a result, they have LDL levels on the order of 300-400 mg/dL and are at the risk of premature heart disease.
11. Brown, M. S., and Goldstein, J. L. (1986). A receptor mediated pathway for cholesterol homeostasis. Science 232, 34-47.
12. Scandinavian Simvastatin Survival Study Group Randomized (1994). Trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). The Lancet 344, 1383-1389.
13. Oliver, M., Poole-Wilson, P., Shepherd, J., and Tikkanen, M. J. (1995). Lower patients'cholesterol now! British Medical Journal 310, 2180-1281.
14. Zetia ® is a registered trademark of MSP Marketing Services © LLD.
15. Vytorin ® is a registered trademark of MSP Marketing Services © LLD.
16. IMPROVE-IT, as well as other Vytorin studies, are summarized at www.clinicaltrials.gov.
17. "Merck and Schering-Plough respond to issues raised about ENHANCE clinical trial" Press Release, January 14, 2008.
18. Kastelein, J. J. P., Akdim, F., Stoes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., GauDet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., and De Groot, E. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine 358, 1431-1443.
19. Berenson, A. (2008). Cholesterol as a danger has its skeptics. New York Times, January 17.
20. Carey, J. (2008). Do cholesterol drugs do any good? Business Week, January 28.
21. Greenland, P., and Lloyd-Jones, D. (2008). Critical Lessons from the ENHANCE trial. Journal of the American Medical Association 299, 953-955.
22. These data can be reviewed on the CDC website: www.cdc.gov.
23. Lansbury, P. (2003). An innovative drug industry? Well, no. The Washington Post, November 16.
24. DiMasi, J. A., and Paquette, C. (2004). The economics of follow-on drug research and development. Trends in entry rates and timing of development. Pharmacoeconomics 22 (Suppl 2), 1-14.
25. Goldammer, A., Wiltschnig, S., Heinz, G., Jansen, M., Stulnig, T., Hrl, W. H., and Derfler, K. (2002). Atorvastatin in low-density lioprotein aphaeresis-treated patients with homozygous and heterozygous familial hypecholesterolemia. Metabolism 51, 976-980.
26. LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Bater, P., Fruchat, J.-C., Gotto, A. M., Green, H., Kastelein, J. J. P., Sheherd, J., and Wenger, N. K., for the Treating to New Targets (TNT) Investigators. (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 352 (14), 1425-1435.
27. Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, A. W., Livingston, S. J., Thompson, J. J., Mackness, M. I., Charlton-Menys, V., and Fuller, J. H. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. The Lancet 364, 685-696.
28. Sever, P. S., Dahlof, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O'Brien, E., and Ostergren, J. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average to lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. The Lancet 361, 1149-1158.
29. Novela, C., and Hennekens, C. H. (2004). Hypothesis: Atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. Journal of Cardiovascular Pharmacology and Therapeutics 9, 61-63.
30. Castro, P. F., Miranda, R., Verdejo, H. E., Greig, D., Gabrielli, L. A., Alcaino, H., Chiong, M., Bustos, C., Garcia, L., Mellado, R., Vukasovic, J. L., Godoy, I., and Lavandero, S. (2008). Pleiotropic effects of atorvastatin in heart failure: Role in oxidative stress, inflammation, endothelial funciton and exercise capacity. Journal of Heart and Lung Transplantation 27, 435-441.
31. Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, Jr., H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, Jr., S. C., and Stone, N. J. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110, 227-239.
32. American Heart Association, Heart Disease and Stroke Statistics, 2005 Update.
33. Franceschini, G. (2000). American Journal of Cardiology 88 (Suppl), 9-13.
34. Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., and Tall, A. R. (1990). Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. New England Journal of Medicine 323, 1234-1238.
35. Avorn, J. (2005). Torcetrapib and atorvastatin-Should marketing drive the research agenda? New England Journal of Medicine 352, 2573-2576.
36. Shear, C. L. (2005). Torcetrapib and atorvastatin. New England Journal of Medicine 353, 1527.
37. Pfizer 2001 Annual Report, page 17.
38. DiMasi, J. A., Hansen, R. W., and Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics 22, 151-185.
39. "The Today Show," September 2, 2004.
40. Psaty, B. M., and Lumley, T. (2008). Surrogate end points and FDA approval. A tale of 2 lipid-altering drugs. Journal of the American Medical Association 299, 1474-1476.
41. Kastelein, J. J., Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Reykin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., and Grobbee, D. E. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomized, double-blind trial. The Lancet 370, 153-160.
42. Mazzone, T. (2007). The Lancet 370, 107-108.
43. Kastelein, J. J., van Leuven, S. I., Burgess, L., Evans, G. W., Kiuvenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., Duggan, W. T., and Bots, M. L., for the RADIANCE Investigators (2007). Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine 356, 1620-1630.
44. Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., and Tuzcu, E. M., for the ILLUSTRATE Investigators (2007). Effect of torcetrapib on the progression of coronary atherosclerosis. New England Journal of Medicine 356, 1304-1315.
45. Medical News Today, April 3, 2007.
46. "The Today Show," September 2, 2004.
47. Consensus Research Stakeholder Value Research, General Public, Phase II, July 2003.
48. Department of Human and Health Services, NIH, Report to Congress on Request to Protect Taxpayers Interests, July 2001.
49. Department of Human and Health Services, NIH, Report to Congress on Affordability of Inventions and Products, July 2004.
50. Morrissey, S. R. Marching in on NIH-funded drugs. Chemical and Engineering News, September 14, 2004.
51. Zycher, B., DiMasi, J. A., and Milne, C.-P. (2008). The truth about drug innovation: Thirty-five summary case histories on private sector contributions to pharmaceutical science, Manhattan Institute for Policy Research, Policy Report No. 6, June 2008, www.manhattan-institute.org/html/mpr_06.htm.
52. Kawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E., Ortaldo, J. R., and O'Shea, J. J. (1994). Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proceedings of the National Academy of Science 91, 6374-6378.
53. Zhou, Y.-J., Chen, M., Cusack, N. A., Kimmell, L. H., Magnuson, K. S., Boyd, J. G., Lin, W., Roberts, J. L., Lengi, A., Buckley, R. H., Geahlen, R. L., Candott, F., Gadina, M., Changelian, P. S., and O'Shea, J. J. (2001). Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for Janus kinases. Cell 8, 959-969.
54. Zhou, Y.-J., Hanson, E. P., Chen, Y.-Q., Magnuson, K., Chen, M., Swann, G., Wange, R. L., O'Shea, J. J., and Changelian, P. S. (1997). Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proceedings of the National Academy of Science 94, 13850-13855.
55. Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., and Leonard, W. J. (1993). Interleukin-2 receptor γ chain: A functional component of the interleukin-7 receptor. Science 262, 1877-1880.
56. Russell, S. M., Keegan, A. D., Harada, N., Nakamura, Y., Noguchi, M., Leland, P., Friedmann, M. C., Miyajima, A., Puri, R. K., Paul, W. E., and Leonard, W. J. (1993). Interleukin-2 receptor γ chain: A functional component of the interleukin-4 receptor. Science 262, 1880-1883.
57. Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., O'Shea, J. J., and Leonard, W. J. (1995). Mutation of JAK3 in a patient with SCID: Essential role of JAK3 in lymphoid development. Science 270, 797-800.
58. Borie, D. C., Changelian, P. S., et al. (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878.
59. Soumerai, S. B., McLaughlin, T. J., Ross-Degnan, D., Casteris, C. S., and Bollini, P. (1994). Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331, 650-655.
60. Cranor, C. W., Bunting, B. A., and Christensen, D. B. (2003). The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care system. Journal of the American Pharmacists Association 43 (2), 173-184.
61. Bozzette, S. A., Joyce, G., McCaffery, D. F., Leibowitz, A. A., Morton, S. C., Berry, S. H., Rastegar, A., Timberlake, D., Shapiro, M. F., and Goldman, D. P. (2001). Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. New England Journal of Medicine 334, 817-823.
62. King James I. (1604). A Counterblaste to Tobacco.
63. Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., Sands, S. B., Schaeffer, E., Schulz, D. W., Tingley, F. D., III, and Williams, K. E. (2007). Pharmacological profile of the α 4 β 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52, 985-994.
64. Coe, J. W., Brooks, P. R., Vetelino, M. G., Witz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., Shrikhande, A., Heym, J. H., Schaeffer, E., Rollema, H., Lu, Y., Mansbach, R. S., Chambers, L. K., Rovetti, C. C., Schulz, D. W., Tingley, D., III, and O'Neill, B. T. (2005). Varenicline: An α 4 β 2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry 48, 3474-3477.
65. FDA News (2008). FDA Issues Public Health Advisory on Chantix (February 1, 2008) www.fda.gov/cder/drug/infopage/varenicline/default.htm.
66. Dunlevy, S. (2007). $ 480 for quit pill. Daily Telegraph, November 13.
67. Pisano, G. P. (2006). Science Business, Harvard Business School Press, Boston.
68. National Center for Health Statistics, Centers for Disease Control Available at http://www.cdc.gov/ nchs.
69. Deng, H. K., Liu, R., Ellmeier, W., Choe S., Unutmaz, D., Burkhart, M., DiMarzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. G., Peiper, S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666.
70. Jenkins, R. (2005). How horrors of the plague made Europe safer from AIDS scourge. The Times (London), March 11.
71. Galvani, A. P., and Slatkin, M. (2003). Evaluating plague and smallpox as historical selective pressures for the CCR5-Δ 32 HIV-resistance allele. Proceedings of the National Academy of Sciences 100, 15276-15279.
72. Williams, J. A., and Pereira, D. A. (2007). Origin and evolution of high throughput screening. British Journal of Pharmacology, 1-9.
73. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchenell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., and Perros, M. (2005). Maraviroc (UK-427,857), a potent, orally bioavailable and selective small molecule inhibitor of a chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents and Chemotherapy 49, 4721-4732.
74. In Europe and other parts of the world, Selzentry is sold as Celsentri.
75. www.Incyte.com/ProductPipeline.
76. Moynihan, R., Heath, I., and Henry, D. (2002). Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal 324, 886-891.
77. Petersen, M. (2008). Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Medicines and Hooked the Nation on Prescription Drugs. Farrar, Straus and Giroux, New York.
78. Abramson, J. (2004). Overdosed America: The Broken Promise of American Medicine, HarperCollins, New York.
79. Cohen, J. S. (2001). Overdose: The Case Against the Drug Companies, Penguin, New York.
80. Hulisz, D. (2004). The burden of illness of irritable bowel syndrome: Current challenges and hope for the future. Journal of Managed Care Pharmacy 10, 299-309.
81. Yehuda, R. (2002). Post-traumatic stress disorder. New England Journal of Medicine 346, 108-114.
82. Horowitz, M. (1976). Stress Response Syndromes, Aronson, Inc., New York.
83. Diagnostic Statistical Manual of Mental Disorders, 4th Edition: DSM-IV, American Psychiatric Association, Washington, DC. 1994.
84. Davidson, J. R. T., Rothbaum, B. O., van derKolk, B. A., Sikes, C. R., and Farfel, G. M. (2001). Multicenter, Double-blind comparison of Sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry 58, 485-492.
85. Brady, K., Pearlstein T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., and Farfel, G. M. (2000). Efficacy and safety of Sertraline treatment of posttraumatic stress disorder. Journal of the American Medical Association 283, 1837-1844.
86. Friedman, M. J., Marmar, C. R., Baker, D. G., Sikes, C. R., and Farfel, G. M. (2007). Randomized double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry 68, 711-720.
87. Hobson, K. (2007). Gain against the pain. Fibromyalgia knowledge and treatment have improved. US News and World Report, October 18.
88. Mease, P. (2005). Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. Journal of Rheumatology 32 (Suppl 75), 6-21.
89. Crofford, L., Simpson, S., Young, J., Haig, G., and Barrett, J. (2007). Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM) trial: A six-month, double-blind, placebo-controlled trial of treatment with pregabalin. Journal of Pain 8 (Suppl 1), S 24.
90. Ricks, D. (2008). List of problem prescription drugs is growing. Newsday, January 21.
91. Sharfstein, J. M., North, M., and Serwint, J. R. (2007). Over the counter but no longer under the radar-Pediatric cough and cold medications. New England Journal of Medicine 357, 2321-2324.
92. Lee, W. M. (2004). Acetaminophen and the U.S. Acute Liver Failure Study Group: Lowering the risks of hepatic failure. Hepatology 40, 6-9.
93. Stipp, D. (2006). Take two possibly lethal pills and call me in the morning. Fortune, February 20.
94. Three excellent reviews on this topic are: (a) Vane, J. R., Bakhle, Y. S., and Botting, R. M. (1998). Cyclooxygenases 1 and 2. Annual Reviews of Pharmacology & Toxicology 38, 97-120.
95. Maziasz, T., Khan, K. N., Talley, J., Gierse, J., and Seibert, K. (2003). The development of drugs that target cyclooxygenase-2, in COX-2 Blockade in Cancer Prevention and Therapy, edited by R. E. Harris, Humana Press, Totowa, NJ, Chapter 16, pp. 259-277.
96. Chandrasekharan, N. V., Dai, H., Roos, L. T., Evanson, N. K., Tomsik, J., Elton, T. S., and Simmons, D. L. (2002). COX-3: A cyclooxygenase variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proceedings of the National Academy of Sciences 99 (21), 13926-13931.
97. Gans, K. R., Galbraith, W., Roman, R. J., Haber, S. B., Kerr, J. S., Schmidt, W. K., Smith, C., Hewes, W. E., and Ackerman, N. R. (1990). Antiinflammatory and safety profile of DuP-697, a novel orally effective prostaglandin synthesis inhibitor. Journal of Pharmacology and Experimental Therapeutics 254, 180-187.
98. Simon, L. S., Weaver, A. L., Graham, D. Y., Kivitz, A. J., Lipsky, P. E., Hubbard, R. C., Isakson, P. C., Verburg, K. M., Yu, S. S., Zhao, W. W., and Geis, G. S. (1999). Antiinflammatory and upper gastrointestinal effects of Celecoxib in rheumatoid arthritis. A randomized controlled trial. Journal of the American Medical Association 282, 1921-1928.
99. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxnius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., and Baron, J. A., for the APPROVe Trail Investigators (2005). Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 352, 1092-1102.
100. Solomon, S. D., McMurray J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., Bertagnolli, M., for the APC Study Investigators (2005). Cardiovascular risk associated with Celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 352, 1071-1080.
101. ADAPT Research Group (2006). Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Antiinflammatory Prevention Trial (ADAPT). Public Library of Science Clinical Trials1:e33 (http://dx.doi.org/10.1371/journal.pctr.0010033).
102. For two examples of such studies see: (a) Hippisley-Cox, J., Coupland, C. (2005). Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors on conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. British Medical Journal 330, 1366-1372.
103. McGettigan, P., and Henry, D. (2006). Cardiovascular risk and inhibition of cyclooxygenas. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Journal of the American Medical Association 296, 1633-1644.
104. www.clinicaltrials.gov Identifier: NCT00346216.
105. Olsen, N. J. (2005). Tailoring arthritis therapy in the wake of the NSAID crisis. New England Journal of Medicine 353, 2578-2580.
106. Appleby, J. (2008). As ads surge, more get Rx's filled. USA Today, March 4.
107. Congressional Budget Office (2006). Research and Development in the Pharmaceutical Industry Publication No. 2589, Washington, DC, October.
108. Data based on the Pharmaceutical Research and Manufacturers of America Annual Survey of 2006.
109. Koizumi, K. (2007). An Update on the FY 2008 R & D Budget AAAS R & D Budget and Policy Program, http://www.aaas.org/spp/rd.
110. Pharmaceutical Research and Manufacturers of America (2008). Pharmaceutical Industry Profile 2008, PhRMA, Washington, DC.
111. Gagnon, M. A., and Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. Public Library of Science Medicine 5 (1), e1dol:10.1371/journal.pmed.0050001.
112. Donohue, J. M., Cevasco, M., and Rosenthal, M. B. (2007). A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 257, 673-681.
113. 10th Annual Survey on Consumer Reaction to DTC Advertising of Prescription Medicines, conducted by Prevention, Men's Health, and Women's Health with assistance from the FDA's Division-Drug Marketing, Advertising and Communication, May 23, 2007, New York.
114. McGlynn, E. A., Asch, M., Adams, J., Keesey, J., Hicks, J., DeCristofaro, A., and Kerr, E. A. (2003). The quality of healthcare delivered to adults in the United States. New England Journal of Medicine 348, 2635-2645.
115. Aikin, K., Swasy, J. L., and Braman, A. C. (2004). Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs-Summary of FDA Survey Research Results Final Report. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, November 19, 2004, Washington, DC.
116. Pharmaceutical Research and Manufacturers of America (2005). PhRMA Guiding Principles. Direct to Consumer Advertisement About Prescription Medicines, PhRMA, Washington, DC.
117. McVary, K. T. (2007). Erectile dysfunction. New England Journal of Medicine 357, 2472-2481.
118. Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., and Mishra, A. (1997). The international index of erectile dysfunction (IIEF): A multidimensional scale for the assessment of erectile dysfunction. Urology 49, 822-830.
119. Galie, N., Ghofrani, H. A. Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., and Simonneau, G., for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 353, 2148-2157.
120. Stiglitz, J. E. (2006). Scrooge and intellectual property rights. British Medical Journal 333, 1279-1280.
121. Barton, N., and Wilhelm, I. (2007). Corporate giving rises modestly. The Chronicle of Philanthropy 19, 1-4.
122. Flanagin, A., and Winkler, M. A. (2006). Theme issue on poverty and human development. Journal of the American Medical Association 296, 2970-2971.
123. Friedrich, M. J., (2007). Ending extreme poverty, improving the human condition. Journal of the American Medical Association 298, 1849-1851.
124. Pandey, P., Sehgal, A. R., Riboud, M., Levine, D., and Goyal, M. (2007). Informing resource-poor populations and the delivery of entitled health and social services in rural India. A cluster randomized controlled trial. Journal of the American Medical Association 298, 1867-1875.
125. Gakidou, E., Oza, S., Fuertes, C. V., Li, A. Y., Lee, D. K., Sousa, A., Hogan, M. C., Vander Horn, S., and Ezzati, M. (2007). Improving child survival through environmental and nutritional interventions. The importance of targeting interventions toward the poor. Journal of the American Medical Association 298, 1876-1887.
126. www.gsk.com/malaria.
127. www.novartisfoundation.org.
128. www.astrazeneca.com.
129. www.sustainability2006.bayer.com.
130. www.merck.com/cr/enabling_access/developing_world.
131. www.diflucanpartnership.org.
132. Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., and Murray, C. J. L., editors (2006). Global Burden of Disease and Risk Factors, Chapter 3, Table 3.6, Harvard University Press, Cambridge, MA. www.dcp2.org/pubs/gbd/3/table/3.6.
133. www.mectizan.com.
134. Bright, G. M., Nagel, A. A., Bordner, J., Desai, K. A., DiBrino, J. N., Nowakowska, J., Vincent, L., Watrous, R. M., Sciavolino, F. C., English, A. R., Retsema, J. A., Anderson, M. R., Brennan, L. A., Borovoy, R. J., Cimochowski, C. R., Faiella, J. A., Girard, A. E., Girard, D., Harbert, C., Manousos, M., and Mason, R. (1988). Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-Aza-homoerythromycin A derivatives; A new class of macrolide antibiotics: The azalides. Journal of Antibiotics 41, 1029-1047.
135. Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A., Haskell, S. L., and Retsema, J. A. (1987). Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 31, 1948-1954.
136. Gladue, R. P., Bright, G. M., Isaacson, R. E., and Newborg, M. F. (1989). In Vitro and In Vivo uptake of Azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33, 277-282.
137. Pliva sells the drug under a different trademark, Sunamed, in Central and Eastern Europe.
138. Cook, J. A. (2008). Eliminating blinding trachoma. New England Journal of Medicine 353, 1777-1779.
139. Solomon, A. W., Harding-Esch, E., Alexander, N. D. E., Aguirre, A., HollAnd, M. J., Bailey, R. K., Foster, A., Mabey, D. C. W., Massae, P. A., Courtright, P., and Shao, J. F. (2008). Two doses of azithromycin to eliminate trachoma in a Tanzanian community. New England Journal of Medicine 358, 1870-1871.
140. Lewis, D., Mulenga, M., Mugyenyi, P., Sagara, I., Wasunna, M., Oduro, A., Sie, A., Tiono, A., Sarkar, S., Kityo, C., Djimde, A., Nambozi, M., Juma, R., Germain, M., Ansah, P., Ouedraogo, A., Aman, R., Kokwaro, G., and Dunne, M. (2007). A Phase 2/3, Randomized, Double Blind, Comparative Trial of Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa. Presented at 5th European Congress of Tropical Medicine & International Health, Amsterdam, The Netherlands, May 24-28, 2007.
141. Chandra, R., Lewis, D., Oduro, A., Mulenga, M., Sagara, I., Sie, A., Tiono, A., Dieng, Y., Oguto, B., Sarkar, S., Ansah, P., Nambosi, M., Djimde, A., Zoungrana, A., Ouedraogo, A., Fall, M., Tina Otieno, L., and Dunne, M. (2007). A Phase 3, Randomized, Open-Label, Comparative Trial of Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of uncomplicated Plasmodium falciparum Malaria in Africa. Presented at 56th Annual Meeting of American Society of Tropical Medicine and Hygiene, Philadelphia, November 4-8, 2007.
142. www.ifpma.org/healthpartnerships.
143. Jordan, G. E. (2008). Where have all the new drugs gone: Industry's medicine cabinet is running empty on compounds. The Newark Star Ledger, January 9.
144. Kaitlin, K. I., and Manocchia, M. (1997). The new drug approvals of 1993, 1994 and 1995: Trends in drug development. American Journal of Therapeutics 4, 46-54.
145. Federal Register (2007). 72, 58103-58106, October 12.
146. Schmid, E. F., and Smith, D. A. (2005). Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today 10, 1031-1039.
147. Barer, S. (2007). Celgene: The pharmaceutical Phoenix. Chemical Heritage Newsmagazine 24, 1-2.
148. Richwine, L., and Heavey, S. (2008). FDA official sees some delays over safety. Reuters, May 27.
149. Tufts Center for the Study of Drug Development (2006). New drugs entering clinical testing in top 10 firms jumped 52% in 2003-2005. Tufts CSDD Impact Report 8 (3), 1-2.
150. www.merck.com/finance/pipeline.swf and www.pfizer.com/files/research/pipeline/2008_0228/ pipeline_208_0228.pdf.
151. Haran, C., and DeVita, V. (2005). The view from the top. Cancer World, Issue 6, 38-43.
152. Folkman, J. (1971). Tumor Angiogenesis: Therapeutic implications. New England Journal of Medicine 285, 1182-1186.
153. Ferrara, N., Hillan, K. J., Gerber, H.-P., and Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGR antibody for treating cancer. Nature Reviews Drug Discovery 3, 391-400.
154. SUGEN was a biotech company first acquired by Pharmacia, which later merged with Pfizer Inc.
155. Faivre, S., Demetri, G., Sargenti, W., and Raymond, E. (2007). Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews Drug Discovery 6, 734-745.
156. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M., and Figlin, R. A. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 356, 115-124.
157. Demetri, G. D., van Oosteroh, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., Desai, J., Fletcher, C. D., George, S., Bello, C. L., Huang, X., Baum, C. M., and Cesali, P. G. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomised controlled trial. Lancet 368, 1329-1338.
158. Herper, M. (2008). Can cancer cure Pfizer? Forbes, June 2.
159. Berenson, A. (2006). Dr. Optimistic. A Pfizer scientist sees research dividends ahead. New York Times, July 18.